Efficacy and safety of adjunctive perampanel treatment in pediatric patients with epilepsy aged 4–12 years: a real-world study

To determine the efficacy and safety of perampanel (PER) as an adjunctive therapy in children aged 4–12 years with epilepsy. We performed a non-randomized, open-label, placebo-uncontrolled, real-world self-controlled study that included 216 young children (aged 4–12 years) with epilepsy who received PER as adjunctive therapy at the children’s hospital affiliated with Chongqing Medical University from July 4, 2020, to September 20, 2023. (1) The efficacy rates of adjunctive PER therapy at 3, 6, 9, and 12 months were 62.8